Society for Immunotherapy of Cancer (SITC) 33rd Annual Conference

Meet with Q2 Solutions at the 2018 SITC Annual Conference and learn how our industry leading precision medicine capabilities can enhance and accelerate your cancer immunology and immunotherapy research

Washington, D.C. | November 07, 2018 - November 11, 2018 | 08:00 - 17:00 Add to Calendar
schedule a meeting

About This Event

Q2 Solutions' deep precision medicine expertise, ranging from biomarkers, companion diagnostics, bioinformatics and analytics can help you deploy disruptive innovation to develop breakthrough precision-medicine therapies. We are committed to help power your immunology and immunotherapy study every step of its development lifecycle, ultimately making the word “cure” a reality for cancer patients everywhere.

Through our Oncology Center of Excellence, our experts in biomarker discovery can provide you with a better understanding of therapeutic targets, molecular signaling, drug biology and patient responses. Utilizing our Genomics capabilities we can begin with biomarker identification programs in early development to identify patients who may respond most appropriately to a particular therapeutic, and then progressively develop candidate biomarkers into research-appropriate tests and market-ready companion diagnostics.

Q2 Solutions’ world-renowned biomarker services scientific staff can help you integrate biological markers across your development plan, from discovery, clinical development, and commercialization. We have the experience and technologies to deliver custom tissue or fluid biomarker assays specifically for your immunology and immunotherapy studies.

Please plan to attend our 5 poster presentations during designated poster hall hours on Friday, Nov. 9th from 8 a.m. – 8 p.m. and Saturday, Nov. 10th from 8 a.m. – 8:30 p.m. in Hall E. A brief overview of our 5 posters are as follows:

1. Robust TMB values derived from tumor-only material
Authors: Natalie Mola, Bioinformaticist and Victor Weigman, Director, Translational Genomics
Abstract ID: 11242

2. A pan-cancer view of the immune landscape in the tumor microenvironment via RNA and their potential for biomarkers in clinical trials
Author: Wendell Jones, Principal Bioinformaticist and Scientific Advisor
Abstract ID: 11151

3. Validated next generation sequencing assay for the characterization of the T-cell repertoire from RNA
Author: Jennifer Sims, Manager, Assay Development and Q2 Solutions | EA Genomics colleagues
Abstract ID: 11310

4. Validated next generation sequencing RNA-based assay of the IGHV mutation status and repertoire diversity
Author: Jeran Stratford, Senior Bioinformaticist and Q2 Solutions | EA Genomics colleagues
Abstract ID: 11156

5. Classification of the human gut microbiome using a validated 16S rRNA next generation sequencing method
Author: Scott Yourstone, Bioinformaticist and Q2 Solutions | EA Genomics colleagues
Abstract ID: 11267

Schedule a meeting with our team at this year’s SITC Annual Conference to learn how we can partner with you in finding the “cure” to cancer by ensuring that the right drug is used to treat the right patient at the right time.

We look forward to meeting you in Washington.

Related Services:

Register for Event

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Biomarker Roadmap to Success

Develop a biomarker roadmap for a successful strategy in developing targeted therapies

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

The importance of bioinformatics in immuno-oncology development

Big data solutions and bioinformatics services for genomic insights

Q2 Solutions Central Laboratory Services

Optimized logistics, deeper science, better insights

Read More